Srilatha Edupuganti

Learn More
The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and monoclonal antibody responses induced by pandemic H1N1 infection in humans. Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced by pandemic(More)
BACKGROUND Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs. METHODS A multicenter, randomized, blinded phase 1 clinical trial evaluated safety and antibody responses after point-of-use(More)
Background.  We report the first-in-human safety and immunogenicity evaluation of a highly attenuated, replication-competent recombinant vesicular stomatitis virus (rVSV) human immunodeficiency virus (HIV)-1 vaccine. Methods.  Sixty healthy, HIV-1-uninfected adults were enrolled in a randomized, double-blinded, placebo-controlled dose-escalation study.(More)
BACKGROUND The efficacy of current influenza vaccines is limited in vulnerable populations. DNA vaccines can be produced rapidly, and may offer a potential strategy to improve vaccine immunogenicity, indicated by studies with H5 influenza DNA vaccine prime followed by inactivated vaccine boost. METHODS Four sites enrolled healthy adults, randomized to(More)
Influenza is the seventh leading cause of death in the United States (Beigel, 2008), with the elderly , the very young, pregnant women, and otherwise immune-compromised populations accounting for >90% of influenza-related deaths. The pandemic H1N1 influenza virus strain is immunologically distinct from other influenza The 2009 pandemic HN influenza pandemic(More)
  • 1